Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.59 |
| ▸ | GSK3B | P49841 | 3/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.59 |
| ▸ | CDC7 | O00311 | 2/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4858358 | 0.77 | CHEK1 (0.74) | CHEK1ROCK2GSK3BIRAK4CDC7 | |
| SCHEMBL4856064 | 0.76 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4CDC7 | |
| SCHEMBL4860069 | 0.76 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4MAP4K4 | |
| SCHEMBL4852451 | 0.75 | ROCK2 (0.70) | CHEK1ROCK2GSK3BIRAK4CDC7 | |
| SCHEMBL4854812 | 0.73 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4CLK4 | |
| SCHEMBL4850874 | 0.73 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4CLK4 | |
| SCHEMBL4847822 | 0.73 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4CDC7 | |
| SCHEMBL7468946 | 0.73 | CYP11B1 (0.42) | — | |
| SCHEMBL4849127 | 0.73 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL4858978 | 0.73 | CHEK1 (1.00) | CHEK1ROCK2GSK3BIRAK4CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885ROCK2 483/4885GSK3B 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.